About Remus Pharmaceuticals Limited
Data last updated: 22 December 2025
Remus Pharmaceuticals Limited is a public limited company based in Ahmedabad, Gujarat, India. It specialises in wholesale trading and distribution, a part of the broader trading and commerce sector. Incorporated on 21 September 2015, the company has been in operation for over 11 years.
Registered with ROC Ahmedabad under CIN U24232GJ2015PLC084536. Listed.
Capital: an authorised share capital of ₹12.5 Cr and a paid-up capital of ₹11.78 Cr. It is led by directors including Swapnil Jatinbhai Shah and Anar Swapnil Shah.
Last AGM: 25 September 2025. Financial statements filed for year ended 31 March 2025. Office: Jayantilal Park, Ahmedabad, Gujarat.
As per the financials filed for FY 2025, the company reported a revenue of ₹625.34 Cr, reflecting significant growth compared to the previous year.
The company has a workforce of approximately 34 employees as per the latest available data.
The company is associated with 1 brand - Remus Pharma. As per MCA filings, the company has open charges of ₹15.66 Cr and satisfied charges of ₹2 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website remuspharma.com.
-
Email**************
-
Telephone**************
-
Website**************
-
Social Media
-
Registered Address1101 To 1103 South Tower One 42 B/H Ashok Vatika Nr.Jayantilal Park Brts Ambli Bopal Roa, D, Ahmedabad, Gujarat, India – 380054
-
IndustryTrading, Wholesale, Other Wholesale
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Remus Pharmaceuticals Limited
Remus Pharmaceuticals Limited has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24232GJ2015PLC084536, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24232GJ2015PLC084536 | Current |
| U24232GJ2015PLC084536 | Previous |
| U24232GJ2015PTC084536 | Previous |
Associated Brands with Remus Pharmaceuticals Limited
Remus Pharmaceuticals Limited operates one associated brand: Remus Pharma. These brands represent Remus Pharmaceuticals Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Remus Pharma is engaged in providing healthcare solutions globally. | remuspharma.com |
Competitors & Alternatives of Remus Pharmaceuticals Limited
Brands and companies operating in the same space as Remus Pharmaceuticals Limited include Pharmaron, Pfizer, Lonza and 6 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Pharmaron
|
Drug discovery and development services for small molecules are provided. | Beijing, China, China | 2003 |
Pfizer
|
Pharmaceutical products for treating multiple diseases are provided. | New York, United States, United States | 1849 |
Lonza
|
CDMO services for pharma, biotech, and specialty ingredients are provided. | Basel, Switzerland, Switzerland | 1897 |
Dotmatics
|
AI powered scientific data management and workflow automation solutions | - | 2005 |
Boehringer Ingelheim
|
Generic drugs and clinical research services are provided globally. | - | 1885 |
LabConnect
|
Laboratory testing, clinical trial research, and biopharma services are provided. | Johnson City, United States, United States | 2002 |
Matchpoint Therapeutics
|
Small molecule medicine development and analytics services are provided. | Cambridge, United States, United States | 2021 |
Lindus Health
|
Contract-based clinical trials and recruitment services are provided. | London, United Kingdom, United Kingdom | 2021 |
Ainos
|
Novel point-of-care testing and low-dose interferon therapeutics are developed. | San Diego, United States, United States | 1986 |
Business Activity of Remus Pharmaceuticals Limited
Remus Pharmaceuticals Limited is engaged in the principal business activity of trade, with detailed activities including wholesale trading.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading | ********* |
Board of Directors of Remus Pharmaceuticals Limited
Remus Pharmaceuticals Limited is currently managed by 7 directors, with 7 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Swapnil Jatinbhai Shah
Also directs:
Espee Therapeutics Llp, Aelius Projects Llp, Senores Pharmaceuticals Limited and 4 more
|
Director | 21 Sep 2015 | 10 Years 9 Months | Current |
|
Anar Swapnil Shah
Also directs:
Espee Global Clinical Trial Services Private Limited, Espee Therapeutics Llp, Aelius Projects Llp and 5 more
|
Director | 30 Dec 2020 | 5 Years 6 Months | Current |
|
Roma Vinodbhai Shah
Also directs:
Relius Lifesciences Private Limited
|
Whole-Time Director | 21 Sep 2015 | 10 Years 9 Months | Current |
|
Vishrut Chandramauli Pathak
Also directs:
Indus Valley Research Llp, Pi Square Bridge Way Advisors Llp, Pi Square Bridge Way Long Short Fund (Ifsc) Llp and 4 more
|
Director | 06 Jan 2023 | 3 Years 6 Months | Current |
| Arpit Deepakkumar Shah | Managing Director | 21 Sep 2015 | 10 Years 9 Months | Current |
| Balwant Purohit | Director | 06 Jan 2023 | 3 Years 6 Months | Current |
Financials of Remus Pharmaceuticals Limited FY 2025 filings available
Remus Pharmaceuticals Limited reported revenue of ₹625.34 Cr (up 190% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Charges & Borrowings of Remus Pharmaceuticals Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 27 Oct 2025 | Others | ₹49.9 Lakh | Open |
| 26 Sep 2025 | Hdfc Bank Limited | ₹10.48 Cr | Open |
| 26 Jun 2025 | Hdfc Bank Limited | ₹2.19 Cr | Open |
| 02 Sep 2024 | Hdfc Bank Limited | ₹1 Cr | Open |
| 26 Feb 2024 | Hdfc Bank Limited | ₹1.5 Cr | Open |
Total charge records: 6 View all charges
Employees and EPFO Compliance at Remus Pharmaceuticals Limited
View historical data on people associated with Remus Pharmaceuticals Limited, including employment history and EPFO contributions.
Employee Count & EPFO Data of Remus Pharmaceuticals Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Remus Pharmaceuticals Limited
GSTIN & GST Filing Data of Remus Pharmaceuticals Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Remus Pharmaceuticals Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Remus Pharmaceuticals Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Remus Pharmaceuticals Limited
MSME Payment Delays by Remus Pharmaceuticals Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Remus Pharmaceuticals Limited
Subsidiaries & Group Companies of Remus Pharmaceuticals Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Remus Pharmaceuticals Limited with ownership details.
MCA Filings & Documents of Remus Pharmaceuticals Limited
MCA Filings & Documents of Remus Pharmaceuticals Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Remus Pharmaceuticals Limited
Frequently Asked Questions about Remus Pharmaceuticals Limited
Remus Pharmaceuticals Limited is an active public limited company in the trading sector based in Ahmedabad, Gujarat, India. It was incorporated on 21 September 2015 (11+ years old) and is registered under CIN L24232GJ2015PLC084536. The company has 34 employees.
Remus Pharmaceuticals Limited reported revenue of ₹625.34 Cr for FY 2025 (up 190.00% YoY).
The current directors of Remus Pharmaceuticals Limited are:
The primary industry of Remus Pharmaceuticals Limited is trading. The company specifically operates in wholesale. The company is currently active in this sector.
Yes, Remus Pharmaceuticals Limited is a listed company.
Remus Pharmaceuticals Limited can be reached at the registered office: 1101 To 1103 South Tower One 42 BH Ashok Vatika Nr.Jayantilal Park Brts Ambli Bopal Roa, D, Ahmedabad, Gujarat, India – 380054, or through the website remuspharma.com.